Bioventus Inc.
General ticker "BVS" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $534.7M (TTM average)
Bioventus Inc. follows the US Stock Market performance with the rate: 9.3%.
Estimated limits based on current volatility of 2.8%: low 8.62$, high 9.11$
Factors to consider:
- Total employees count: 930 (-4.1%) as of 2024
- US accounted for 41.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Strategic risks and growth management, Supply chain disruptions, Acquisition/divestiture risks, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.13$, 14.72$]
- 2025-12-31 to 2026-12-31 estimated range: [7.93$, 14.34$]
Financial Metrics affecting the BVS estimates:
- Positive: with PPE of 22.8 at the end of fiscal year the price was low
- Positive: -4.75 < Operating profit margin, % of -2.05
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of -1.37 <= -0.16
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 3.29 > -0.63
- Negative: Industry earnings per price (median), % of -4.09 <= 0
- Positive: 0.01 < Operating cash flow per share per price, % of 5.55
Short-term BVS quotes
Long-term BVS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $512.12MM | $508.77MM | $572.99MM |
| Operating Expenses | $679.35MM | $590.49MM | $584.97MM |
| Operating Income | $-167.23MM | $-81.72MM | $-11.98MM |
| Non-Operating Income | $-21.79MM | $-39.39MM | $-37.15MM |
| Interest Expense | $12.02MM | $40.68MM | $38.79MM |
| R&D Expense | $23.85MM | $13.45MM | $13.64MM |
| Income(Loss) | $-189.03MM | $-121.11MM | $-49.13MM |
| Taxes | $-44.37MM | $0.09MM | $-5.29MM |
| Other Income(Loss) | $-68.74MM | $-74.43MM | $0.00MM |
| Profit(Loss)* | $-158.70MM | $-156.23MM | $-33.54MM |
| Stockholders Equity | $325.24MM | $173.59MM | $147.94MM |
| Inventory | $84.77MM | $91.33MM | $92.47MM |
| Assets | $1,372.65MM | $810.91MM | $727.96MM |
| Operating Cash Flow | $-13.54MM | $15.34MM | $38.80MM |
| Capital expenditure | $1.48MM | $7.36MM | $1.01MM |
| Investing Cash Flow | $-116.44MM | $15.81MM | $22.96MM |
| Financing Cash Flow | $62.08MM | $-26.65MM | $-54.58MM |
| Earnings Per Share** | $-2.59 | $-2.49 | $-0.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.